Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN016 Combination Therapy in Advanced Non-Small Cell Lung Cancer
NCT06868732Phase 1Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Apr 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JSKN016 in non-small cell lung cancer (NSCLC) (8 arms), sponsored by Alphamab Oncology. Primary endpoints: Objective Response Rate up to 24 months and Adverse Events up to 24 months. Started Apr 2025; status: recruiting.
02
Drugs
JSKN016
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06868732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868732.